Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Up 5.8% – What’s Next?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON)’s stock price traded up 5.8% during mid-day trading on Thursday . The stock traded as high as $20.06 and last traded at $20.1280. 195,300 shares were traded during trading, a decline of 27% from the average session volume of 267,891 shares. The stock had previously closed at $19.02.

Analyst Ratings Changes

ETON has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 13th. Zacks Research upgraded shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Craig Hallum raised their price target on shares of Eton Pharmaceuticals from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, March 3rd. Finally, HC Wainwright boosted their price target on shares of Eton Pharmaceuticals from $35.00 to $37.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $31.00.

Eton Pharmaceuticals Price Performance

The stock has a market cap of $552.36 million, a P/E ratio of -82.04 and a beta of 1.19. The business has a 50 day simple moving average of $16.50 and a 200-day simple moving average of $17.32. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.25 and a current ratio of 1.63.

Institutional Trading of Eton Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in ETON. State of Alaska Department of Revenue purchased a new position in Eton Pharmaceuticals in the third quarter valued at about $30,000. Quarry LP bought a new position in shares of Eton Pharmaceuticals during the 3rd quarter valued at approximately $37,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Eton Pharmaceuticals during the 4th quarter worth approximately $44,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Eton Pharmaceuticals during the 2nd quarter worth approximately $37,000. Finally, Legal & General Group Plc bought a new stake in shares of Eton Pharmaceuticals in the 2nd quarter worth approximately $41,000. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.